title: Experiences of Somatonorm in Sweden.
abstract: About 180 patients in Sweden are currently receiving treatment with somatrem; a majority of them have previously received pituitary hGH. A high incidence of antibody formation was noted in patients without prior pituitary hGH treatment, but growth velocity was not decreased in these patients. Antibodies developed in about 15% of patients previously treated with pituitary hGH. Adverse effects occurred in four patients within 3 weeks of commencing therapy, but were temporary and treatment could be continued.
authors.forename: O
authors.initials: O
authors.lastname: Westphal
mesh_terms: D000328:Adult; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D013006:Growth Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000172:deficiency / Q000276:immunology / Q000627:therapeutic use; D019382:Human Growth Hormone; D006801:Humans; D007223:Infant; D008297:Male; D013548:Sweden
chemical_list: D019382:Human Growth Hormone; D013006:Growth Hormone